Varenicline Tartrate Tablet, Film Coated
Product Images NDC 85742-015

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Varenicline Tartrate (NDC 85742-015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kanchan Healthcare Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Containerlabel1mg (Containerlabel1mg)

This is a description of varenicline tablets with the NDC 85742-016-15. The tablets come with a Medication Guide for each patient and should be stored at temperatures not exceeding 26°C (77°F). Each tablet contains 1.71 mg equivalent to 1 mg of medicine. The tablets are dispensed in child-resistant packaging. The manufacturing details indicate that they are produced by Modley Pharmaceuticals Ltd. in Daman, India, and distributed by Kanchan Healthcare Inc. in Parsippany, NJ, USA.*

FDA Label Image

Containerlabelpoint5mg (Containerlabelpoint5mg)

This text provides information about a medication labeled as NDC 85742-015-15, with storage instructions to keep it at 25°C (77°F) with excursions allowed between 15-30°C (59-86°F). The medication contains varenicline tartrate, and each tablet includes 0.85 mg of varenicline. The manufacturer is listed as Medley Pharmaceuticals Ltd., and it is dispensed by Kanchan Healthcare Inc. The prescription is for varenicline tablets.*

FDA Label Image

Continuingmonthbox (Continuingmonthbox)

FDA Label Image

Continuingpack (Continuingpack)

FDA Label Image

Startingmonthbox (Startingmonthbox)

FDA Label Image

Startingpack (Startingpack)

FDA Label Image

Varenicline-01 (Varenicline 01)

FDA Label Image

Varenicline-02 (Varenicline 02)

FDA Label Image

Varenicline-03 (Varenicline 033)

FDA Label Image

Varenicline-04 (Varenicline 04)

This is a chart showing the continuous abstinence rate over weeks of treatment with Varericline at a dosage of 1.0mg BID. The chart displays the abstinence rates at different intervals ranging from 25/13 weeks to 52/40 weeks.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.